| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2006-10-16 13:00:12 UTC |
|---|
| Update Date | 2022-03-07 02:49:25 UTC |
|---|
| HMDB ID | HMDB0005012 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Olanzapine |
|---|
| Description | Olanzapine was the third atypical antipsychotic to gain approval by the Food and Drug Administration (FDA) and has become one of the most commonly used atypical antipsychotics. Olanzapine has been approved by the FDA for the treatment of schizophrenia, acute mania in bipolar disorder, agitation associated with schizophrenia and bipolar disorder, and as maintenance treatment in bipolar disorder and psychotic depression. It has also been established in treating depression off-label because of its mood-stabilizing properties and its ability to increase the efficacy of antidepressants. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company. It is available as a pill that comes in the strengths of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg and as as Zydis orally disintegrating tablets in the strengths of 5 mg, 10 mg, 15 mg, and 20 mg. It is also available as a rapid-acting intramuscular injection for short term acute use. Olanzapine (oh-LAN-za-peen, sold as Zyprexa, Zydis, or in combination with fluoxetine, as Symbyax) was the third atypical antipsychotic to gain approval by the Food and Drug Administration (FDA) and has become one of the most commonly used atypical antipsychotics. Olanzapine has been approved by the FDA for the treatment of schizophrenia, acute mania in bipolar disorder, agitation associated with schizophrenia and bipolar disorder, and as maintenance treatment in bipolar disorder and psychotic depression. |
|---|
| Structure | CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3 |
|---|
| Synonyms | | Value | Source |
|---|
| Olanzapina | ChEBI | | Olanzapinum | ChEBI | | Zyprexa | ChEBI | | Lanzac | HMDB | | Zyprexa intramuscular | HMDB | | Zyprexa zydis | HMDB | | Zolafren | HMDB | | 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine | HMDB | | Olanzapine pamoate | HMDB |
|
|---|
| Chemical Formula | C17H20N4S |
|---|
| Average Molecular Weight | 312.432 |
|---|
| Monoisotopic Molecular Weight | 312.14086735 |
|---|
| IUPAC Name | 5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0³,⁷]tetradeca-1(14),3(7),5,8,10,12-hexaene |
|---|
| Traditional Name | zyprexa |
|---|
| CAS Registry Number | 132539-06-1 |
|---|
| SMILES | CN1CCN(CC1)C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 |
|---|
| InChI Identifier | InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3 |
|---|
| InChI Key | KVWDHTXUZHCGIO-UHFFFAOYSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as benzodiazepines. These are organic compounds containing a benzene ring fused to either isomers of diazepine(unsaturated seven-member heterocycle with two nitrogen atoms replacing two carbon atoms). |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Benzodiazepines |
|---|
| Sub Class | Not Available |
|---|
| Direct Parent | Benzodiazepines |
|---|
| Alternative Parents | |
|---|
| Substituents | - Benzodiazepine
- Thieno-para-diazepine
- 2,3,5-trisubstituted thiophene
- Para-diazepine
- N-methylpiperazine
- N-alkylpiperazine
- N-arylated-2-aminothiophene
- 1,4-diazinane
- Piperazine
- 2-aminothiophene
- Benzenoid
- Imidolactam
- Heteroaromatic compound
- Thiophene
- Tertiary aliphatic amine
- Tertiary amine
- Azacycle
- Secondary amine
- Amidine
- Carboxylic acid amidine
- Propargyl-type 1,3-dipolar organic compound
- Organic 1,3-dipolar compound
- Hydrocarbon derivative
- Organonitrogen compound
- Organic nitrogen compound
- Amine
- Organopnictogen compound
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | |
|---|
| Disposition | |
|---|
| Process | Not Available |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | Not Available | Not Available | | LogP | Not Available | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections| Adduct Type | Data Source | CCS Value (Å2) | Reference |
|---|
| [M+H]+ | CBM | 175.5 | 30932474 |
|
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 2.31 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 10.1764 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 3.48 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 86.4 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 999.3 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 209.2 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 135.9 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 169.0 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 53.6 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 318.4 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 365.8 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 365.3 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 765.3 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 244.4 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 917.3 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 193.1 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 234.6 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 331.7 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 364.4 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 125.6 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Olanzapine,1TMS,isomer #1 | CC1=CC2=C(S1)N([Si](C)(C)C)C1=CC=CC=C1N=C2N1CCN(C)CC1 | 2783.4 | Semi standard non polar | 33892256 | | Olanzapine,1TMS,isomer #1 | CC1=CC2=C(S1)N([Si](C)(C)C)C1=CC=CC=C1N=C2N1CCN(C)CC1 | 2712.8 | Standard non polar | 33892256 | | Olanzapine,1TMS,isomer #1 | CC1=CC2=C(S1)N([Si](C)(C)C)C1=CC=CC=C1N=C2N1CCN(C)CC1 | 3958.9 | Standard polar | 33892256 | | Olanzapine,1TBDMS,isomer #1 | CC1=CC2=C(S1)N([Si](C)(C)C(C)(C)C)C1=CC=CC=C1N=C2N1CCN(C)CC1 | 2934.8 | Semi standard non polar | 33892256 | | Olanzapine,1TBDMS,isomer #1 | CC1=CC2=C(S1)N([Si](C)(C)C(C)(C)C)C1=CC=CC=C1N=C2N1CCN(C)CC1 | 2915.9 | Standard non polar | 33892256 | | Olanzapine,1TBDMS,isomer #1 | CC1=CC2=C(S1)N([Si](C)(C)C(C)(C)C)C1=CC=CC=C1N=C2N1CCN(C)CC1 | 4032.0 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Olanzapine GC-MS (Non-derivatized) - 70eV, Positive | splash10-0btd-8090000000-3a1771a0db51f3e9472b | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Olanzapine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Olanzapine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Olanzapine LC-ESI-qTof , Positive-QTOF | splash10-03dj-0940000000-1103f40c5bb833e12903 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Olanzapine LC-ESI-qTof , Positive-QTOF | splash10-03dj-0940000000-37cb2e8fb99c38b097b8 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Olanzapine LC-ESI-qTof , Positive-QTOF | splash10-0a4i-2790000000-bdc5a34b08715b752eef | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Olanzapine LC-ESI-QTOF , positive-QTOF | splash10-03di-0009000000-256a6e976b00468fe839 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Olanzapine LC-ESI-QTOF , positive-QTOF | splash10-03di-0049000000-83ee647255e8d18f2b5c | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Olanzapine LC-ESI-QTOF , positive-QTOF | splash10-0a4i-0090000000-81810b42dccae4ee9ab6 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Olanzapine LC-ESI-QTOF , positive-QTOF | splash10-0bt9-0490000000-8994262c6a309d663713 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Olanzapine LC-ESI-QTOF , positive-QTOF | splash10-01ot-0950000000-ceb0ca01cefbd1da57d7 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Olanzapine , positive-QTOF | splash10-03di-0149000000-e74851873e2fbaa6c182 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Olanzapine , positive-QTOF | splash10-03dj-0940000000-1103f40c5bb833e12903 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Olanzapine , positive-QTOF | splash10-03dj-0940000000-37cb2e8fb99c38b097b8 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Olanzapine , positive-QTOF | splash10-03di-0149000000-338b982664cf3019be13 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Olanzapine , positive-QTOF | splash10-0a4i-2790000000-bdc5a34b08715b752eef | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Olanzapine 50V, Positive-QTOF | splash10-01ot-0950000000-fe416acb0e50253f8d17 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Olanzapine 40V, Positive-QTOF | splash10-0bt9-0490000000-a203abf5daf6a6c6e069 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Olanzapine 20V, Positive-QTOF | splash10-03di-0049000000-4b7427c44443aab6c7a1 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Olanzapine 30V, Positive-QTOF | splash10-0a4i-0090000000-15b5422aefe3fc372956 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Olanzapine 10V, Positive-QTOF | splash10-03di-0009000000-d71ce384c72fd5835dac | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Olanzapine 50V, Positive-QTOF | splash10-01ot-0950000000-7ba8fbea8f79ae64960d | 2021-09-20 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Olanzapine 10V, Positive-QTOF | splash10-03di-0019000000-66bcbe5560546ebe79ae | 2016-06-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Olanzapine 20V, Positive-QTOF | splash10-03di-0097000000-7386f41b122664655390 | 2016-06-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Olanzapine 40V, Positive-QTOF | splash10-03k9-5980000000-82c2110f56cd7202848e | 2016-06-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Olanzapine 10V, Negative-QTOF | splash10-03di-0039000000-01aa4f818b0cb4798c0f | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Olanzapine 20V, Negative-QTOF | splash10-0300-0092000000-cee214399c7899dbbc41 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Olanzapine 40V, Negative-QTOF | splash10-0a6u-2490000000-dec2f8d13b50769ec96e | 2016-08-03 | Wishart Lab | View Spectrum |
|
|---|
| General References | - Cerdan LF, Guevara MA, Sanz A, Amezcua C, Ramos-Loyo J: Brain electrical activity changes in treatment refractory schizophrenics after olanzapine treatment. Int J Psychophysiol. 2005 Jun;56(3):237-47. [PubMed:15866327 ]
- Horak EL, Jenkins AJ: Postmortem tissue distribution of olanzapine and citalopram in a drug intoxication. J Forensic Sci. 2005 May;50(3):679-81. [PubMed:15932107 ]
- Yamada K, Isotani T, Irisawa S, Yoshimura M, Tajika A, Yagyu T, Saito A, Kinoshita T: EEG Global Field Power spectrum changes after a single dose of atypical antipsychotics in healthy volunteers. Brain Topogr. 2004 Summer;16(4):281-5. [PubMed:15379228 ]
- Mortimer A, Martin S, Loo H, Peuskens J: A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. Int Clin Psychopharmacol. 2004 Mar;19(2):63-9. [PubMed:15076013 ]
- Merrick TC, Felo JA, Jenkins AJ: Tissue distribution of olanzapine in a postmortem case. Am J Forensic Med Pathol. 2001 Sep;22(3):270-4. [PubMed:11563738 ]
|
|---|